Pharmaceutical

Sanofi signs radioligand therapy licensing deal for rare cancers

Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.

Sep 14, 2024 - 04:00
Sanofi signs radioligand therapy licensing deal for rare cancers
Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.
Read the original article

Tags:

Previous Article

Into the unknown: How quickly can vaccines be developed for Disease X

Next Article

Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likel...

Apr 21, 2024

Tanden, Becerra, Califf make time for a meeting with tobacco lobbyists on the menthol ban

Tanden, Becerra, Califf make time for a meeting with to...

Nov 29, 2023

Mirum applies for extended use of PFIC therapy in Europe

Mirum applies for extended use of PFIC therapy in Europe

Apr 6, 2023